OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
NLH56

Nova Leap Health Corp

Healthcare Facilities & ServicesVerified

Nova Leap Health Corp maintains a relatively strong liquidity position, with a current ratio of 1.78, indicating the company can cover its short-term liabilities with its short-term assets. The company's cash and equivalents amount to $1,116,760, while its long-term debt is $1,248,940, resulting in a net cash position that is negative after subtracting total debt. The debt-to-equity ratio of 0.07 suggests a conservative capital structure with minimal leverage. In terms of profitability, the company's return on equity (ROE) is 2.59%, and its return on assets (ROA) is 2.27%, both of which are below the industry median for healthcare facilities and services. The operating margin is 3.36%, and the net profit margin is 7.35%, indicating that the company is generating a modest profit relative to its revenue. The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to regional economic or regulatory risks. The company's growth trajectory is not clearly defined in the available data, as there are no specific revenue growth projections or historical growth rates provided. The capital expenditure for the period is reported as $0, suggesting that the company is not currently investing in new physical assets. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could affect its ability to fund operations without external financing. The dilution risk is low, and there are no significant adjustments applied to the valuation metrics. Recent events, such as analyst estimates, show that the last actual EPS was -$0.01, and the last actual revenue was $35,325,000. These figures suggest that the company is currently reporting a small loss per share, which may impact investor sentiment and stock performance.

30-day price · NLH(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyNova Leap Health Corp
TickerNLH.V
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Nova Leap Health Corp operates in the healthcare sector, providing pharmaceutical services and equipment, and generates revenue primarily through its healthcare facilities and services.

Classification. Nova Leap Health Corp is classified under the Healthcare Facilities & Services industry within the Healthcare Services & Equipment business sector, with a classification confidence of 0.92.

Nova Leap Health Corp maintains a relatively strong liquidity position, with a current ratio of 1.78, indicating the company can cover its short-term liabilities with its short-term assets. The company's cash and equivalents amount to $1,116,760, while its long-term debt is $1,248,940, resulting in a net cash position that is negative after subtracting total debt. The debt-to-equity ratio of 0.07 suggests a conservative capital structure with minimal leverage. In terms of profitability, the company's return on equity (ROE) is 2.59%, and its return on assets (ROA) is 2.27%, both of which are below the industry median for healthcare facilities and services. The operating margin is 3.36%, and the net profit margin is 7.35%, indicating that the company is generating a modest profit relative to its revenue. The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to regional economic or regulatory risks. The company's growth trajectory is not clearly defined in the available data, as there are no specific revenue growth projections or historical growth rates provided. The capital expenditure for the period is reported as $0, suggesting that the company is not currently investing in new physical assets. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could affect its ability to fund operations without external financing. The dilution risk is low, and there are no significant adjustments applied to the valuation metrics. Recent events, such as analyst estimates, show that the last actual EPS was -$0.01, and the last actual revenue was $35,325,000. These figures suggest that the company is currently reporting a small loss per share, which may impact investor sentiment and stock performance.
Key takeaways
  • Nova Leap Health Corp has a conservative capital structure with a low debt-to-equity ratio of 0.07.
  • The company's ROE and ROA are below the industry median, indicating lower profitability relative to peers.
  • The company's liquidity is moderate, with a current ratio of 1.78, but its net cash position is negative after subtracting total debt.
  • The company's revenue is concentrated in a single segment, with no geographic diversification disclosed.
  • The company is not currently investing in new physical assets, as indicated by a capital expenditure of $0.
  • The company's recent financial performance shows a small loss per share, which may affect investor confidence.
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$6.4M
Gross profit$2.4M
Operating income$215.9k
Net income$473.1k
R&D
SG&A
D&A
SBC
Operating cash flow$374.3k
CapEx$0.00
Free cash flow$623.4k
Total assets$20.8M
Total liabilities$2.5M
Total equity$18.3M
Cash & equivalents$1.1M
Long-term debt$1.2M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$21.3M$3.0M$1.8M$2.6M
FY-3$28.2M-$1.8M-$835.8k$448.9k
FY-2$26.2M-$795.4k-$1.1M-$197.6k
FY-1$25.8M$636.0k$1.4M$1.9M
FY0$31.5M$981.7k-$189.9k$643.2k
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$26.8M$18.5M$1.7M
FY-3$23.9M$18.7M$1.3M
FY-2$20.9M$18.2M$894.8k
FY-1$22.4M$18.2M$1.4M
FY0$23.5M$19.0M$1.5M
PeriodOCFCapExFCFSBC
FY-4$2.2M$0.00$2.6M
FY-3$1.0M-$71.2k$448.9k
FY-2$2.2M-$28.0k-$197.6k
FY-1$1.4M-$25.0k$1.9M
FY0$1.6M$0.00$643.2k
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$6.4M$215.9k$473.1k$623.4k
FQ-6$6.3M$193.3k$227.0k$365.9k
FQ-5$6.4M$91.9k-$207.9k-$61.7k
FQ-4$6.6M$134.9k$886.3k$1.0M
FQ-3$7.1M$26.2k-$78.3k$118.5k
FQ-2$8.0M$323.0k-$484.0k-$275.1k
FQ-1$8.3M$375.4k$426.2k$659.6k
FQ0$8.1M$257.1k-$53.7k$140.2k
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$20.8M$18.3M$1.1M
FQ-6$21.0M$18.3M$1.2M
FQ-5$21.0M$18.4M$1.4M
FQ-4$22.4M$18.2M$1.4M
FQ-3$23.2M$18.2M$1.3M
FQ-2$23.6M$18.7M$1.4M
FQ-1$23.6M$18.8M$1.6M
FQ0$23.5M$19.0M$1.5M
PeriodOCFCapExFCFSBC
FQ-7$374.3k$0.00$623.4k
FQ-6$762.0k$365.9k
FQ-5$1.0M-$61.7k
FQ-4$1.4M-$25.0k$1.0M
FQ-3$196.8k$118.5k
FQ-2$808.7k-$275.1k
FQ-1$1.3M$659.6k
FQ0$1.6M$0.00$140.2k
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$18.3M
Net cash-$132.2k
Current ratio1.8
Debt/Equity0.1
ROA2.3%
ROE2.6%
Cash conversion79.0%
CapEx/Revenue0.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricNLHActivity
Op margin3.4%7.7% medp25 -2.4% · p75 15.5%below median
Net margin7.4%5.9% medp25 -3.8% · p75 12.8%above median
Gross margin38.0%45.5% medp25 31.1% · p75 62.9%below median
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue0.0%-7.0% medp25 -14.9% · p75 -3.2%top quartile
Debt / equity7.0%25.0% medp25 3.8% · p75 63.3%below median
Observations
IR observations
Last actual EPS-0.01 USD
Last actual revenue35,325,000 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-07 01:50 UTC#de99b1eb
Market quoteclose USD 0.39 · shares 0.09B diluted
no public URL
2026-05-03 20:29 UTC#3aee7a6c
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 18:23 UTCJob: 609f1598